{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=24",
    "query": {
      "condition": "Phase II",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 21412,
    "total_pages": 2142,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T17:56:44.416Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01258855",
      "title": "Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Recurrent Melanoma",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Ziv-Aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2011-01-18",
      "completion_date": "2018-03-29",
      "has_results": true,
      "last_update_posted_date": "2019-05-10",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 21,
      "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 14 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01258855"
    },
    {
      "nct_id": "NCT00669578",
      "title": "CC-4047 in Treating Patients With Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Secondary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "CC-4047",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 77,
      "start_date": "2008-05",
      "completion_date": "2019-12-12",
      "has_results": true,
      "last_update_posted_date": "2019-12-30",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669578"
    },
    {
      "nct_id": "NCT04788043",
      "title": "Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Classic Hodgkin Lymphoma",
        "Relapsed Classical Hodgkin Lymphoma",
        "Refractory Classic Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Magrolimab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "PET/CT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ranjana Advani",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2022-06-21",
      "completion_date": "2025-08-29",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 2,
      "location_summary": "Stanford, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04788043"
    },
    {
      "nct_id": "NCT01460940",
      "title": "A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Lymphocyte Depletion Hodgkin Lymphoma",
        "Adult Lymphocyte Predominant Hodgkin Lymphoma",
        "Adult Mixed Cellularity Hodgkin Lymphoma",
        "Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma",
        "Adult Nodular Sclerosis Hodgkin Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "panobinostat",
          "type": "DRUG"
        },
        {
          "name": "lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2011-10-13",
      "completion_date": "2016-11-16",
      "has_results": true,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Columbus, Ohio",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01460940"
    },
    {
      "nct_id": "NCT00058149",
      "title": "Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-09-21",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 60,
      "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Aurora, Colorado + 46 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058149"
    },
    {
      "nct_id": "NCT00007449",
      "title": "Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DPC 083",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dupont Applied Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Newport Beach, California • Bradenton, Florida + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00007449"
    },
    {
      "nct_id": "NCT01527149",
      "title": "Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage I Mantle Cell Lymphoma",
        "Stage II Contiguous Mantle Cell Lymphoma",
        "Stage II Non-Contiguous Mantle Cell Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage IV Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 37,
      "start_date": "2011-12-06",
      "completion_date": "2024-01-11",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01527149"
    },
    {
      "nct_id": "NCT03529955",
      "title": "Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatomyositis, Adult Type"
      ],
      "interventions": [
        {
          "name": "Apremilast 30mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tulane University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-06-12",
      "completion_date": "2021-04-07",
      "has_results": true,
      "last_update_posted_date": "2023-03-03",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03529955"
    },
    {
      "nct_id": "NCT05610826",
      "title": "Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neuroendocrine Tumor",
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "cytoreductive surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)",
          "type": "DRUG"
        },
        {
          "name": "Peptide receptor radionuclide therapy (PRRT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-03-07",
      "completion_date": "2024-09-11",
      "has_results": false,
      "last_update_posted_date": "2024-10-26",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05610826"
    },
    {
      "nct_id": "NCT04816643",
      "title": "Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2 Infection, COVID-19"
      ],
      "interventions": [
        {
          "name": "Biological/Vaccine: BNT162b2 10mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 20mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 30mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Biological/Vaccine: BNT162b2 3mcg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "6 Months to 15 Years"
      },
      "enrollment_count": 11837,
      "start_date": "2021-03-24",
      "completion_date": "2023-12-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-11-15T17:56:44.416Z",
      "location_count": 90,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04816643"
    }
  ]
}